The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors.

ABSTRACT:

Purpose

There are few effective biomarkers for neuroendocrine tumors. Precision oncology strategies have provided liquid biopsies for real-time and tailored decision-making. This has led to the development of the first neuroendocrine tumor liquid biopsy (the NETest). The NETest represents a transcriptomic signature of neuroendocrine tumor (NETs) that captures tumor biology and disease activity. The data have direct clinical application in terms of identifying residual disease, disease progress and the efficacy of treatment. In this overview we assess the available published information on the metrics and clinical efficacy of the NETest.

Material and methods

Published data on the NETest have been collated and analyzed to understand the clinical application of this multianalyt

SUBMITTER: Malczewska A 

PROVIDER: S-EPMC7453408 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature